{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:24:43Z","timestamp":1764937483827,"version":"3.41.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Antibody-drug conjugates (ADCs) have emerged as a treatment option for patients with relapsed\/refractory multiple myeloma with the regulatory approval of the first-in-class B-cell maturation antigen (BCMA) ADC belantamab mafodotin. Other BCMA and non-BCMA ADCs are currently in clinical development. Whereas ADCs allow antigen-specific delivery of a chemomoiety to myeloma cells, on-target and off-target effects related to antigen target, antibody, linker, and chemomoiety can also limit these approaches. We review the clinical development of belantamab mafodotin and ongoing efforts to enhance its efficacy while mitigating ocular toxicity. The landscape of other ADCs being evaluated clinically in patients with multiple myeloma will also be reviewed.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000628","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T14:02:14Z","timestamp":1668520934000},"page":"488-495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Antibody Drug Conjugates in Multiple Myeloma"],"prefix":"10.1097","volume":"28","author":[{"given":"Christopher J.","family":"Ferreri","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250620","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib2-20250620","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"bib3-20250620","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"bib4-20250620","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"bib5-20250620","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib6-20250620","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib7-20250620","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","year":"2022","journal-title":"eJHaem"},{"key":"bib8-20250620","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib9-20250620","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib10-20250620","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"bib11-20250620","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib12-20250620","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","year":"2019","journal-title":"Blood Cancer J"},{"key":"bib13-20250620","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","year":"2021","journal-title":"Cancer"},{"key":"bib14-20250620","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","year":"2020","journal-title":"Blood Cancer J"},{"issue":"suppl 16","key":"bib15-20250620","first-page":"8018","article-title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 study","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"bib16-20250620","first-page":"8019","article-title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"bib17-20250620","first-page":"897","article-title":"DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed\/refractory multiple myeloma","volume":"138","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"bib18-20250620","first-page":"8017","article-title":"Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-6 arm-a interim analysis","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"bib19-20250620","first-page":"19","article-title":"DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib\/dexamethasone (bordex) in relapsed\/refractory multiple myeloma (RRMM)","volume":"136","year":"2020","journal-title":"Blood"},{"issue":"S3","key":"bib20-20250620","first-page":"1596","article-title":"P942: DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma","volume":"6","year":"2022","journal-title":"Hema"},{"issue":"suppl 16","key":"bib21-20250620","first-page":"TPS8073","article-title":"Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"S3","key":"bib22-20250620","first-page":"1603","article-title":"P946: a phase I\/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMARC 19-02 BELACARD STUDY","volume":"6","year":"2022","journal-title":"Hema"},{"issue":"suppl 1","key":"bib23-20250620","first-page":"1653","article-title":"Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed\/refractory multiple myeloma (RRMM)","volume":"138","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"bib24-20250620","first-page":"164","article-title":"S178: safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: a phase 1\/2 study by the Hellenic Society of Hematology","volume":"6","year":"2022","journal-title":"Hema"},{"issue":"suppl 1","key":"bib25-20250620","first-page":"1670","article-title":"Belantamab mafadotin in patients with relapsed\/refractory AL amyloidosis with myeloma","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib26-20250620","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"bib27-20250620","first-page":"26","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib28-20250620","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib29-20250620","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression","volume":"27","year":"2021","journal-title":"Clin Cancer Res"},{"key":"bib30-20250620","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review","volume":"13","year":"2021","journal-title":"Cancer"},{"key":"bib31-20250620","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells","volume":"20","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"bib32-20250620","first-page":"9","article-title":"The anti\u2013B-cell maturation antigen (BCMA) antibody-\u03b1-amanitin conjugate HDP-101 induces immunogenic cell death and immunologic memory in models of multiple myeloma","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib33-20250620","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nature14418","article-title":"TP53 loss creates therapeutic vulnerability in colorectal cancer","volume":"520","year":"2015","journal-title":"Nature"},{"key":"bib34-20250620","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","year":"2018","journal-title":"Front Immunol"},{"issue":"S3","key":"bib35-20250620","first-page":"170","article-title":"S181: modakafusp alfa (Tak-573): updated clinical, pharmacokinetic (PK), and immunogenicity results from a phase 1\/2 study in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"6","year":"2022","journal-title":"Hema"},{"issue":"suppl 1","key":"bib36-20250620","first-page":"1867","article-title":"A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)\u2013refractory, including pts relapsed\/refractory (R\/R) or na\u00efve to daratumumab (dara)","volume":"134","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"bib37-20250620","first-page":"4763","article-title":"A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib38-20250620","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-016-0380-0","article-title":"Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies","volume":"10","year":"2017","journal-title":"J Hematol Oncol"},{"key":"bib39-20250620","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib40-20250620","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-human phase I study of ABBV-838, an antibody-drug conjugate targeting SLAMF7\/CS1 in patients with relapsed and refractory multiple myeloma","volume":"26","year":"2020","journal-title":"Clin Cancer Res"},{"key":"bib41-20250620","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","year":"2019","journal-title":"Blood Cancer J"},{"key":"bib42-20250620","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood.V128.22.4470.4470","article-title":"SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib43-20250620","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56\u2013positive multiple myeloma","volume":"19","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib44-20250620","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma","volume":"19","year":"2014","journal-title":"Front Biosci"},{"key":"bib45-20250620","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study","volume":"8","year":"2021","journal-title":"Lancet Haematol"},{"key":"bib46-20250620","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","year":"2016","journal-title":"J Clin Investig"},{"key":"bib47-20250620","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"bib48-20250620","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","year":"2013","journal-title":"Br J Haematol"},{"key":"bib49-20250620","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:10:31Z","timestamp":1750443031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000628","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}